Trial Profile
A 52 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Parallel, Treat-to-target Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (BEGIN: BB T1 LONG).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN; BEGIN-BB-T1-LONG
- Sponsors Novo Nordisk
- 01 May 2012 Results published in the Lancet.
- 08 Dec 2011 Results presented at the 21st World Diabetes Congress.
- 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.